SALT LAKE CITY, USA, June 30, 2019 LSK BioPharma (or “LSKB”), a US-based biopharmaceutical firm and Jiangsu Hengrui Medicine, Co., Ltd. (SHA:600276, or “Hengrui”), one of the largest and most innovative fully-integrated biopharmaceutical companies based in China, today announced the first
LSK BioPharma Announces Preliminary Review of Top-Line Results from ANGEL Study SALT LAKE CITY, USA, June 27, 2019 – LSK BioPharma (LSKB) has completed the unblinding and preliminary review of topline data from its ANGEL Study, a Phase III clinical trial for
Job Title Clinical Trial Associate (CTA) Job Status Full Time Job Summary The Clinical Trial Associate (CTA) supports at least one primary project, and depending on scope and phase of project, may support multiple projects. The CTA provides support to one or more Clinical
Job Title Senior Scientists, Clinical Job Status Full Time Job Summary The senior clinical scientist will be a key player of a multi-disciplinary, matrix team ensuring that scientific issues are appropriately considered with respect to highly complex clinical data findings. This individual
Job Title Principal Medical Writer Job Status Full Time Job Summary The Principal Medical Writer is responsible for authoring documents, including clinical study reports (CSRs), protocols, investigator’s brochures, publications and other documents. This position is also expected to contribute to higher level submission documents.
Business Development/Safety Project Management Associate. Work within the pharmaceutical industry practices and standards for new drug development and safety reporting. Organize aggregate safety data including adverse events, concomitant medications and lab data. Prepare and lead safety oversight meetings for global
SALT LAKE CITY, USA, and SHANGHAI, CHINA, April 8, 2019 -- LSK BioPharma (or “LSKB”), a US-based biopharmaceutical firm and Jiangsu Hengrui Medicine, Co., Ltd. (SHA:600276, or “Hengrui”), one of the largest and most innovative fully-integrated biopharmaceutical companies based in
SALT LAKE CITY, USA, Feb 12, 2019 -- LSK BioPharma (LSKB, Company) announced that it has reached the pre-specified number of events required for unblinding and analysis of the primary endpoint of overall survival in the ANGEL study, a global
SALT LAKE CITY, USA, Feb 2nd, 2019 – In order to accommodate rapid growth, LSK BioPharma (LSKB, Company) has relocated its corporate headquarters to 2825 E Cottonwood Pkwy, Suite 180, Salt Lake City, Utah 84121 USA. The new offices will
Overview We are currently seeking a full-time, San Francisco office-based CMC Senior Director to join LSK BioPharma. This position will manage and guide our API and CMC activities for our small molecule drug substance and product programs from preclinical through commercial. If
